Jungaberle A

Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Psychiatry and Psychotherapy, Campus Charité Mitte, Berlin, Germany.

7 papers

ArticlePsilocybin

Long-Term Efficacy of Psilocybin with Adjunct Psychotherapy in Treatment-Resistant Major Depression: 6- and 12-Month Naturalistic Follow-Up of a Phase 2b Trial.

Mertens LJ, Betzler F, Brand M +24

Europe PMC2026
ArticlePsilocybin

Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression: The EPISODE Randomized Clinical Trial.

Mertens LJ, Koslowski M, Betzler F +23

Europe PMC2026
ArticlePsilocybin

Compassionate use of psilocybin for treatment-resistant depression in Germany.

Gründer G, Mertens LJ, Jungaberle A +2

Europe PMC2026
ArticlePsychedelics

Key competencies for psychedelic treatment in real-world mental health care settings.

Wolff M, Rutrecht H, Gründer G +2

Europe PMC2025
ArticlePsychedelics

Decreased CO<sub>2</sub> saturation during circular breathwork supports emergence of altered states of consciousness.

Havenith MN, Leidenberger M, Brasanac J +12

Europe PMC2025
ArticlePsilocybin

Psilocybin as a Disease-Modifying Drug—A Salutogenic Approach in Psychiatry.

Spangemacher M, Mertens LJ, Färber LV +3

Europe PMC2024
ArticlePsilocybin

Methodological challenges in psychedelic drug trials: Efficacy and safety of psilocybin in treatment-resistant major depression (EPIsoDE) - Rationale and study design.

Mertens LJ, Koslowski M, Betzler F +9

Europe PMC2022